20 articles
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
Drugs typically used to suppress immunity paradoxically enhance cancer treatment when combined with immunotherapy.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
New research reveals how SIRT2 regulates T cell responses, potentially improving cancer immunotherapy and immune function.
New research reveals why giving multiple doses of a promising type 1 diabetes treatment doesn't improve outcomes beyond a single course.
New research reveals metformin can silence HIV and boost immune control, offering hope for treatment-free remission.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Daratumumab monotherapy showed promising results in treating refractory lupus nephritis by reducing inflammation and fibrosis.
Swedish study finds JAK inhibitors raise keratinocyte cancer risk by 39% compared to TNF inhibitors in RA patients.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
A German proof-of-concept trial tests whether a maximal five-class antiretroviral regimen can deplete latent HIV reservoirs.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
